Severe immune deficiency follows autologous stem cell transplantation for multiple myeloma and is associated with significant infectious morbidity. This study was designed to evaluate the utility of a pre-transplant vaccine and infusion of a primed autologous T cell product in stimulating specific immunity to influenza.
Introduction
Epidemics of influenza A virus strains have been associated with hospitalization of approximately 200,000 people per year in the United States with 30,000-50,000 deaths per year. The case fatality rates have been estimated to be 0.5/100,000 in the 0-49 year age range and as high as 100/100,000 in the >65 year age range [1] [2] [3] . The primary method to combat influenza is the administration of a vaccine appropriate to the seasonal infecting strains.
Patients with compromised immunity are at particularly high risk of complications from influenza infection and yet have less protection from vaccination 4, 5 . Patients with malignancy have an increased attack rate of influenza and data suggest that 10-40% of oncology patients are infected during each seasonal epidemic 6 . This is higher than in the general population where the case rate is usually 5-15%.
Multiple myeloma is one example of a population particularly at risk for severe influenza 7, 8 . Patients have severe humoral and cellular immune deficiency 9, 10 . This is associated with impaired responses against both tumor, microbial, and vaccine antigens [11] [12] [13] [14] . Furthermore, therapy with high dose melphalan and autologous stem cell transplantation (ASCT) is used frequently for the treatment of relapsed or refractory disease 15, 16 . Though hematopoietic recovery after ASCT occurs within 3 weeks, full recovery of T-and B-cell function may take months to years and vaccine responses are typically poor [17] [18] [19] [20] [21] . Patients postFor personal use only. on November 16, 2017 . by guest www.bloodjournal.org From ASCT have increased morbidity associated with respiratory viruses in general 22, 23 . This, coupled with a higher attack rate, the potential for prolonged shedding, and the emergence of resistant viruses, mandates that improved preventive strategies be developed 24, 25 .
The altered number, function and dynamics of immune cell recovery after ASCT for myeloma increases patient risk for serious infections such as VZV, CMV, S. pneumoniae, and influenza 26 . In particular, influenza accounts for 20% of respiratory virus infections in the transplant patients 27 . The ability to respond to influenza vaccination is impaired well beyond the quantitative repletion of lymphocytes 13, 28 . Strategies to accelerate and augment the recovery and function of autologous T-cells after transplant for myeloma may be beneficial.
In this study, we examined whether immunization with the seasonal influenza vaccine would be immunogenic in patients with myeloma undergoing ASCT and whether sustained influenza-specific protective responses could be elicited after ASCT. Our data demonstrate that vaccine-primed autologous T cell infusions are associated with restoration of antigen-specific antibody production.
Combined vaccination and adoptive transfer represents a powerful strategy to improve host defenses post-ASCT.
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Methods

Study Design
Patients for this randomized, controlled study were recruited from the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, PA. This study was distinct from a prior study investigating the timing of an autologous T cell product and pneumococcal vaccine responses 29 . The study protocol was approved by the University of Pennsylvania institutional review board and informed consent was obtained from patients in accordance with the Declaration of Helsinki. The analysis plan was determined before study initiation and laboratory assays were performed in a blinded fashion.
Eligible patients were patients with symptomatic multiple myeloma scheduled to receive an ASCT on a companion study (UPCC 13406, ClinicalTrials.gov Blood samples from patients undergoing ASCT were obtained at baseline, prior to steady-state T-cell harvest, and on days +14, + 60, +100 and +180 after stem cell infusion. Patients were examined during these time points and clinical events recorded.
T cell Infusions
Patients underwent apheresis to collect >1 X 10 9 mononuclear cells. For the Primed Group, this procedure was scheduled 14 days after the first vaccine. The cells were depleted of monocytes and cryopreserved. The T cell manufacturing process has been described previously and consisted of CD3 and CD28 beadbased stimulation 30 . All infused T cell products were required to meet FDAspecified safety and release criteria prior to infusion. The target number of T cells for infusion was ≈5 X 10 10 T cells. 
Statistical analysis
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The comparison of the study's endpoints measured repeatedly over time was carried out using the mixed effects models and/or the generalized estimating equations (GEE) method. The longitudinal assessments of the outcomes were statistically tested using a repeated measures model with the following three main effects: The overall group differences, the overall changes over time, and the interaction effect. Baseline measurements for both groups were used as covariates to adjust for potential group differences at baseline. The independent t-test or the Mann-Whitney test was used for the comparisons of responder frequency and seroconversion. The geometric mean titers were calculated using the standard formula: n-th root of (X 1 )(X 2 )..(X n ). The 95% confidence intervals of the geometric mean titers were calculated by taking the anti-log of the 95% confidence intervals of the arithmetic means of the log-transformed values. Due to the study design and the large number of needed comparisons, corrections for multiple comparisons were not performed. Significance was set at p<0.05. 
Results
Patients
Hemagglutination Inhibition (HAI) Assay Results
The primary endpoint of this study was antibody response to influenza as measured by the serotype-specific influenza hemagglutinin inhibition antibody responses. HAI titer is the parameter with strongest correlation to protection from wild type infection 35, 36 . H3N2, and H1N1 HAI geometric mean titers were higher at all time points after vaccination in the Primed patients compared to the Nonprimed Patients (Figure 2) . Titers in the Non-primed Group remained near baseline throughout all time points. A mixed effects model was used to define the differences in geometric mean titers over time between the two arms. A significant difference was seen comparing the Primed and the Non-primed patients' responses to the H1N1 (p=0.006) and H3N2 (p<0.0001) components of the vaccine. Influenza B HAI geometric mean titers exhibited no difference between the two groups (p=NS) and this may reflect its weaker immunogenicity 37, 38 .
We defined seroconversion as the percentage of patients with a 4-fold or greater increase in HAI titer after immunization. Seroconversion for H1N1 occurred in 36% of the Primed Group and 10% of the Non-primed Group (p=0.31).
Seroconversion for H3N2 occurred in 72% of the Primed Group and 0% of the 
B-cell and T-cell recovery kinetics
ASCT usually leads to a sustained immune deficiency [17] [18] [19] [20] [21] [39] [40] [41] . We examined Bcell and T-cell recovery kinetics to understand the landscape of the immune system after ASCT. It is clear that the provision of the autologous T cell product led to rapid quantitative reconstitution of both the B cell and T cell compartments (Figures 3 and 4) . The kinetics of recovery were similar in both groups. At baseline, the majority of B cells had a naïve phenotype (IgM+, CD27-). At day 14 post ASCT, B cells reached a nadir and the majority had a switched memory phenotype (IgM-, CD27+). The GEE method was used to define group and time effects in this repeated measure study design. There was a significant change in total B cell counts (p=0.01) and naïve B cell counts over time (p=0.001). For switch memory B cells (CD27+IgM-), there was no significant change in the absolute counts over time.
For
The provision of an autologous T cell infusion has been previously shown to quantitatively restore both CD4 and CD8 T cells 30 . In this study, we examined functionally distinct T cell subsets. T cell recovery differed dramatically between CD4 and CD8 T cells, however, there were no differences between the Primed and Non-primed Groups. CD4 Effector Memory T cells were the most highly retained cell type, while CD4 Naïve, CD4 Central Memory, and CD4 Reverted Memory cells remained depressed for a sustained period of time. In contrast, CD8 Naïve, CD8 Central Memory, and CD8 Reverted Memory all increased after the infusion of the autologous T cell product. None of the CD8 T cell subsets exhibited a group effect when analyzed by GEE. The Naïve CD8 and Reverted Memory CD8 T cells exhibited a significant time effect (p<0.001 and p=0.05, respectively). The apparent difference in CD8 Effector Memory populations between the Primed Group and the Non-primed Group is not significant and is due to three outliers with engraftment syndrome 30 . Therefore, there were no differences in T cell subsets between the two arms.
Autologous T cell infusions have been demonstrated previously to retain a diverse and consistent T cell repertoire after in vitro expansion
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, however, the retention of the repertoire after infusion has not been previously investigated.
We identified the fraction of abnormal Vβ families (oligoclonal or <10% of the average signal in controls) after spectratyping 43 . Approximately half of the Vβ families were abnormal and there were no differences between the two groups or across time points (data not shown). Approximately 60% of the Vβ families For personal use only. on November 16, 2017. by guest www.bloodjournal.org From exhibited no change from time point to time point. Therefore, the repertoire appears to be largely stable within the host.
Studies of T-and B-cell responsiveness
In principle, the mechanism of enhanced vaccine response after a priming dose could be due to either recruitment of antigen-specific memory T cells carried over from the priming at the time of the post-ASCT vaccine 44 To assess the T cell responses, γ-interferon-producing T cells were measured after stimulation with a cocktail of T cell epitope peptides. The patients in the Primed Group trended towards a higher CD8 T cell response than the patients in the Non-primed Group, however, the difference did not reach statistical significance. The inactivated influenza vaccine stimulates predominantly CD4 T cell responses 45 . We therefore measured T cell ELISPOT results after depletion of CD8 T cells and found that CD4-specific responses were significantly better in the Primed group at the T cell harvest time point (p=0.02) ( Figure 5 ). Finally, to ensure that there were no global differences between the ability of the two groups of patients to respond to stimuli, responses to PMA and ionomycin were measured. There were no differences between the two patient groups ( Figure 5 ).
We then analyzed whether early T cell and B cell responses were associated with subsequent specific antibody production independently of the study group. 
Clinical Correlates of influenza vaccine responses
There were no differences between the Primed and Non-primed groups in terms of demographics, medications, hospitalizations, or baseline CD3, CD19, ALC, or ANC. Four patients developed engraftment syndrome and all were in the Nonprimed group. Two of these four received short courses of steroids. No subject developed community acquired influenza and sought medical attention. We considered whether any of the clinical variables might influence HAI responses.
Age, gender, race, dexamethasone prior to enrollment, bortezomib prior to enrollment, baseline CD3, baseline CD19, baseline ANC, and baseline ALC were examined using the Wilcoxon test for association with HAI seroconversion status.
None of the variables were statistically associated with seroconversion. Study subjects also received the conjugated pneumococcal vaccine as a control and we evaluated the concordance between pneumococcal responses and HAI seroconversion. We defined a pneumococcal responder by summing the responses to four serotypes and defining a four-fold increase from baseline.
There was no association between HAI responders and pneumococcal responders. Overall, 21% of enrolled subjects (all primed with the conjugated pneumococcal vaccine) were pneumococcal responders, much lower than the 73% overall responder frequency seen in the Primed group for influenza seroconversion.
Discussion
This study demonstrates that seasonal influenza vaccination priming prior to autologous T cell collection, ASCT, infusion of autologous T cells and repeat influenza vaccination leads to superior influenza vaccine responses in patients with multiple myeloma compared to the Non-primed patients. The importance of this result is two-fold. Infection is one of the most common causes of death after transplantation for multiple myeloma 26, 27 . This is thought to be a consequence of the age at the time of transplant and the natural immune suppression arising after high-dose melphalan. The provision of an autologous co-stimulated and expanded T cell product may improve the outcome by augmenting host responses to infection. In this study, the provision of the autologous T cell product did not restore vaccine responses unless the patient and the T cell product had been primed by prior antigen exposure. Even though both groups of patients had full T cell recovery after melphalan, the Non-primed group did not respond to the post-transplant vaccine. Therefore, this strategy could be broadly applicable in transplant patients where influenza is a common pathogen with high morbidity 27 . The second implication of this work is that this strategy could be harnessed for improved tumor vaccine responses, where responses to date have been compromised by poor T cell function post-ASCT 18 .
In a prior study, we explored an approach of combination immunotherapy with the 7-valent pneumococcal conjugate vaccine and adoptive T-cell 29 . We At the time of the study design, follicular helper T cells (T FH cells) were not welldefined and we did not perform flow cytometric identification of these cells 49 . We hypothesize that the autologous T cell product contained antigen-specific T FH cells, which contributed to the B cell maturation and subsequent production of HAI antibodies.
This study contributes to the growing body of knowledge regarding the provision of antigen-specific defenses to immune compromised patients. Achieving the goal broadly could markedly improve the survival of patients with multiple myeloma who undergo ASCT. In this patient population, infection is the most common cause of morbidity 7, 8, 18, 27 . In addition, harnessing antigen-specific immunity for tumor vaccines will become increasingly important as immunebased therapies become a reality 50 . 
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